Patent Assignment
Reel/Frame 029928/0839
Assignment of Assignor's Interest
Recorded: 2013-03-05
Pages: 9
Assignor
EISAI, INC.
Executed: 2013-02-20
Assignee
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
4787 LEVY STREET, MONTREAL, QUEBEC, H4R 2P9, CANADA
Covered Properties
(3)
Compounds Having Selective Activity for Retinoid X Receptors, and Means for Modulation of Processes Mediated by Retinoid X Receptors
Patent:
5,962,731 →
Application:
08/472,784 →
Compounds Having Selective Activity for Retinoid X Receptors, and Means for Modulation of Processes Mediated by Retinoid X Receptors
Patent:
5,780,676 →
Application:
08/485,386 →
Compounds Having Selective Activity for Retinoid X Receptors, and Means for Modulation of Processes Mediated by Retinoid X Receptors
Application:
13/444,651 →
Related Assignments
(3)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Aug 6, 2008
From: LIGAND PHARMACEUTICALS INCORPORATED; SERAGEN, INC.
To: EISAI INC.
Reel/Frame 021339/0344 →
Security Interest
Jul 18, 2016
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.
To: BARCLAYS BANK PLC
Reel/Frame 039380/0385 →
Release of Security Interest
Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.
Reel/Frame 070778/0199 →